세계의 복합부위 통증 증후군 시장 : 시장 규모 분석(치료 종류별, 질환 종류별, 유통 채널별, 지역별) 및 예측(2022-2032년)

Global Complex Regional Pain Syndrome (CRPS) Market is valued at approximately USD 0.1 billion in 2023 and is anticipated to expand at a steady compound annual growth rate (CAGR) of 2.80% over the forecast period from 2024 to 2032. Complex Regional Pain Syndrome, a chronic and often debilitating condition marked by severe pain, changes in skin color and temperature, and swelling, continues to challenge the neurological and pain management communities globally. Despite being relatively rare, its disproportionate impact on quality of life and functionality has garnered growing clinical attention. Recent advances in diagnostic imaging and nerve-targeted treatment pathways have paved the way for early-stage intervention, while multimodal therapeutic approaches combining pharmacological and non-pharmacological modalities are becoming standard protocol.

The rise in post-traumatic and post-surgical CRPS cases, particularly among orthopedic patient populations, is fueling market growth. Clinical initiatives are increasingly emphasizing personalized care pathways incorporating sympathetic nerve blocks, ketamine infusions, physical therapy, corticosteroids, and bisphosphonates, which can provide symptom relief when tailored precisely. Simultaneously, the advent of wearable neuromodulation devices and spinal cord stimulation technologies reflects an industry-wide pivot towards innovation in non-opioid pain management. However, underdiagnosis, diagnostic ambiguity, and insurance coverage limitations for experimental treatments continue to pose significant barriers, especially in emerging markets.

To overcome these challenges, strategic collaborations between academic research centers, rehabilitation institutes, and pharmaceutical developers are intensifying. This multidisciplinary convergence is leading to breakthroughs in understanding CRPS's neuropathophysiology and the formulation of targeted therapies. Notably, the role of biomarkers in early detection and the exploration of immunological underpinnings are shaping future treatment pipelines. Governments and advocacy groups are concurrently pushing for standardized clinical guidelines and broader reimbursement frameworks to improve patient access to comprehensive treatment regimens.

North America currently holds a significant share in the global CRPS treatment landscape, owing to a mature healthcare infrastructure, higher rates of elective surgeries (a risk factor), and early adoption of advanced neuromodulation devices. Europe follows closely, supported by a well-established physiotherapy and pain management network and increasing clinical research funding. Meanwhile, Asia Pacific is projected to witness the fastest growth, underpinned by a large patient population, rising awareness, and government investments in pain rehabilitation programs across countries such as India, China, and Japan. Latin America and the Middle East & Africa are gradually expanding due to enhanced access to specialist clinics and evolving regulatory ecosystems.

Major market player included in this report are:

• Teva Pharmaceutical Industries Ltd.
• Medtronic plc
• Johnson & Johnson
• Abbott Laboratories
• Bayer AG
• Pfizer Inc.
• Grunenthal GmbH
• Novartis AG
• Sanofi S.A.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Purdue Pharma L.P.
• Mallinckrodt Pharmaceuticals
• Merck & Co., Inc.
• Boston Scientific Corporation

The detailed segments and sub-segment of the market are explained below:

By Therapy Type

• Pharmacological Therapy
• Physical Therapy
• Sympathetic Nerve Block
• Spinal Cord Stimulation
• Others

By Disease Type

• CRPS I
• CRPS II
• CRPS-NOS (Not Otherwise Specified)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Complex Regional Pain Syndrome Market Executive Summary

• 1.1. Global Complex Regional Pain Syndrome Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Therapy Type
  • 1.3.2. By Disease Type
• 1.4. Key Trends
• 1.5. Reimbursement & Coverage Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Complex Regional Pain Syndrome Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability of Advanced Therapies
    • 2.3.3.2. Clinical Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Competitive Landscape
    • 2.3.3.5. Economic Viability (Payer Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Clinical Guidelines & Standards
    • 2.3.4.2. Technological Advancements in Diagnostics
    • 2.3.4.3. Patient Awareness & Advocacy
    • 2.3.4.4. Reimbursement Frameworks
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Complex Regional Pain Syndrome Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Rising Post-traumatic and Post-surgical Incidence
  • 3.1.2. Adoption of Neuromodulation and Wearable Therapies
  • 3.1.3. Growth in Personalized, Multimodal Treatment Protocols
• 3.2. Market Challenges
  • 3.2.1. Underdiagnosis and Clinical Ambiguity
  • 3.2.2. Insurance Coverage Limitations for Advanced Therapies
• 3.3. Market Opportunities
  • 3.3.1. Digital Health & Tele-Rehabilitation Platforms
  • 3.3.2. Biomarker-Driven Early Diagnosis
  • 3.3.3. Expansion of Spinal Cord Stimulation Adoption

Chapter 4. Global Complex Regional Pain Syndrome Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's Model
  • 4.1.7. Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspectives
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Complex Regional Pain Syndrome Market Size & Forecasts by Therapy Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. CRPS Market: Therapy Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 5.2.1. Pharmacological Therapy
  • 5.2.2. Physical Therapy
  • 5.2.3. Sympathetic Nerve Block
  • 5.2.4. Spinal Cord Stimulation
  • 5.2.5. Others

Chapter 6. Global Complex Regional Pain Syndrome Market Size & Forecasts by Disease Type 2022-2032

• 6.1. Segment Dashboard
• 6.2. CRPS Market: Disease Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
  • 6.2.1. CRPS I
  • 6.2.2. CRPS II
  • 6.2.3. CRPS-NOS

Chapter 7. Global Complex Regional Pain Syndrome Market Size & Forecasts by Region 2022-2032

• 7.1. North America CRPS Market
  • 7.1.1. U.S. CRPS Market
    • 7.1.1.1. Therapy Type breakdown size & forecasts, 2022-2032
    • 7.1.1.2. Disease Type breakdown size & forecasts, 2022-2032
  • 7.1.2. Canada CRPS Market
• 7.2. Europe CRPS Market
  • 7.2.1. UK CRPS Market
  • 7.2.2. Germany CRPS Market
  • 7.2.3. France CRPS Market
  • 7.2.4. Spain CRPS Market
  • 7.2.5. Italy CRPS Market
  • 7.2.6. Rest of Europe CRPS Market
• 7.3. Asia Pacific CRPS Market
  • 7.3.1. China CRPS Market
  • 7.3.2. India CRPS Market
  • 7.3.3. Japan CRPS Market
  • 7.3.4. Australia CRPS Market
  • 7.3.5. South Korea CRPS Market
  • 7.3.6. Rest of Asia Pacific CRPS Market
• 7.4. Latin America CRPS Market
  • 7.4.1. Brazil CRPS Market
  • 7.4.2. Mexico CRPS Market
  • 7.4.3. Rest of Latin America CRPS Market
• 7.5. Middle East & Africa CRPS Market
  • 7.5.1. Saudi Arabia CRPS Market
  • 7.5.2. South Africa CRPS Market
  • 7.5.3. Rest of Middle East & Africa CRPS Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. Teva Pharmaceutical Industries Ltd.
  • 8.1.2. Medtronic plc
  • 8.1.3. Johnson & Johnson
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. Teva Pharmaceutical Industries Ltd.
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Abbott Laboratories
  • 8.3.3. Bayer AG
  • 8.3.4. Pfizer Inc.
  • 8.3.5. Grunenthal GmbH
  • 8.3.6. Novartis AG
  • 8.3.7. Sanofi S.A.
  • 8.3.8. Eli Lilly and Company
  • 8.3.9. GlaxoSmithKline plc
  • 8.3.10. Purdue Pharma L.P.
  • 8.3.11. Mallinckrodt Pharmaceuticals
  • 8.3.12. Merck & Co., Inc.
  • 8.3.13. Boston Scientific Corporation

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes